Stock A298380 ABL BIO INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials ABL Bio Inc.

Equities

A298380

KR7298380007

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 21/05/2024 am IST 		5-day change 1st Jan Change
25,400 KRW -0.59% Intraday chart for ABL Bio Inc. +7.86% +3.25%
25/03 Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates CI
2023 ABL Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI

Valuation

Fiscal Period: December 2021 2022 2024 2025
Capitalization 1 10,41,424 10,99,129 12,16,470 -
Enterprise Value (EV) 1 10,41,424 10,99,129 12,16,470 12,16,470
P/E ratio -23.8 x - -55.5 x -41.5 x
Yield - - - -
Capitalization / Revenue - 16.8 x 34.8 x 43.4 x
EV / Revenue - 16.8 x 34.8 x 43.4 x
EV / EBITDA - 454 x -55.3 x -40.5 x
EV / FCF - - -13.7 x -12.5 x
FCF Yield - - -7.32% -7.97%
Price to Book - - 20.4 x 38.8 x
Nbr of stocks (in thousands) 47,123 47,788 47,893 -
Reference price 2 22,100 23,000 25,400 25,400
Announcement Date 12/08/22 15/03/23 - -
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2024 2025
Net sales 1 - 65.33 35 28
EBITDA 1 - 2.42 -22 -30
EBIT 1 - 0.1186 -24 -31
Operating Margin - 0.18% -68.57% -110.71%
Earnings before Tax (EBT) 1 - - -22 -29
Net income 1 -43.56 - -22 -29
Net margin - - -62.86% -103.57%
EPS 2 -927.0 - -458.0 -612.0
Free Cash Flow 3 - - -89,000 -97,000
FCF margin - - -2,54,285.71% -3,46,428.57%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 12/08/22 15/03/23 - -
1KRW in Billions2KRW3KRW in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2024 2025
Net Debt - - - -
Net Cash position - - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow 1 - - -89,000 -97,000
ROE (net income / shareholders' equity) - - -31.2% -64.3%
ROA (Net income/ Total Assets) - - -13.8% -22.1%
Assets 2 - - 159.4 131.2
Book Value Per Share 3 - - 1,248 654.0
Cash Flow per Share - - - -
Capex 2 - - - -
Capex / Sales - - - -
Announcement Date 12/08/22 15/03/23 - -
1KRW in Million2KRW in Billions3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ABL BIO INC. Stock ABL Bio Inc.
+3.25% 900M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+7.90% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+13.06% 107B
BIONTECH SE Stock BioNTech SE
-12.88% 22.31B
ARGENX SE Stock argenx SE
-3.99% 21.6B
BEIGENE, LTD. Stock BeiGene, Ltd.
-6.20% 18.23B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.93% 17.62B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.08% 14.26B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+32.66% 12.37B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-28.25% 8.28B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A298380 Stock
  4. Financials ABL Bio Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW